Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada

Smith-Palmer, J.; Takizawa, C.; Valentine, W.

doi:10.1186/s12894-019-0448-6

BMC Urology

Table 4 Quality of life in men with prostate cancer

From: Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada

Study (year)	Health state	Mean (SD or 95% CI) utility value
Study (year)	Health state	EQ-5D	EORTC-8D	PORPUS-U	HUI-2	HUI-3	QWB
France
Sullivan et al. (2007) [54]	Metastatic hormone refractory prostate cancer, baseline	0.669
Germany
Sullivan et al. (2007) [54]	Metastatic hormone refractory prostate cancer, baseline	0.527
UK
Sullivan et al. (2007) [54]	Metastatic hormone refractory prostate cancer, baseline	0.715
Hall et al. (2015) [45]	Baseline, at diagnosis	0.838
	9 months post-diagnosis	0.868
	15 months post-diagnosis	0.868
Lloyd et al. (2015) [55]	MCRPC asymptomatic/mildly symptomatic before chemotherapy	0.830 (0.126)	0.856 (0.089)
	MCRPC symptomatic before chemotherapy	0.625 (0.173)	0.697 (0.118)
	MCRPC currently receiving chemotherapy	0.692 (0.219)	0.750 (0.117)
	MCRPC post chemotherapy	0.700 (0.183)	0.753 (0.133)
Watson et al. (2016) [56]	Diagnosed with prostate cancer in previous 9–24 months (overall)	0.852 (0.173)
	No moderate/big problem with urine function	0.868 (0.160)
	No moderate/big problem with bowel function	0.862 (0.166)
	No moderate/big problem with sexual function	0.861 (0.176)
	Moderate/big problem with urine function	0.773 (0.222)
	Moderate/big problem with bowel function	0.653 (0.195)
	Moderate/big problem with sexual function	0.838 (0.170)
Canada
Krahn et al. (2013) [57]	Prostate cancer survivors (overall)			0.91 (0.08)	0.85 (0.15)	0.78 (0.24)
Krahn et al. (2007) [58]	Localized prostate cancer receiving radical prostatectomy, radiation, or hormonal therapy	0.84			0.87	0.81	0.61
	Metastatic disease	0.84			0.86	0.82	0.63
	Stable patients	0.85			0.86	0.81	0.63
Ku et al. (2009) [59]	Patients undergoing radical prostatectomy, baseline (pre-surgery)			0.94 (0.93–0.95)
	Patients undergoing radical prostatectomy, 0–3 months post surgery			0.81 (0.79–0.82)
	Patients undergoing radical prostatectomy, 3–9 months post surgery			0.87 (0.86–0.89)
	Patients undergoing radical prostatectomy, 9–18 months post surgery			0.89 (0.87–0.90)
	Patients undergoing radical prostatectomy, 18–30 months post surgery			0.90 (0.88–0.91)
Sullivan et al. (2007) [54]	Metastatic hormone refractory prostate cancer, baseline	0.750
Gries et al. (2016) [60]	Men at risk for prostate cancer				0.83 (0.168)	0.77 (0.238)
	Men with prostate cancer				0.83 (0–124)	0.75 (0.260)
	General population				0.87 (0.136)	0.84 (0.178)
Bremner et al. (2007) [61]	Men with prostate cancer (overall population)					0.80 (0.19)	0.65 (0.13)

MCRPC metastatic hormone resistant prostate cancer

Back to article page

ISSN: 1471-2490

Contact us

General enquiries: journalsubmissions@springernature.com